ВОСПАЛЕНИЕ И РАК ТОЛСТОЙ КИШКИ. МОЛЕКУЛЯРНОИММУНОЛОГИЧЕСКИЕ МЕХАНИЗМЫ
PDF

Как цитировать

Кит, О., Никипелова, Е., Шапошников, А., Златник, Е., Новикова, И., Францинян, Е., Владимирова, Л., Шатова, Ю., Шевченко, А. ., & Позднякова, В. (2018). ВОСПАЛЕНИЕ И РАК ТОЛСТОЙ КИШКИ. МОЛЕКУЛЯРНОИММУНОЛОГИЧЕСКИЕ МЕХАНИЗМЫ. Вопросы онкологии, 64(1), 34–40. https://doi.org/10.37469/0507-3758-2018-64-1-34-40

Аннотация

После анализа данных зарубежной литературы остается много спорных вопросов о влиянии воспаления на развитие рака толстой кишки. Молекулярные механизмы в различных формах колоректального рака различаются и во многом связаны с воспалительными заболеваниями кишечника. Есть некоторые иммунологические сходства и различия между колит-ассоциированным раком толстой кишки, возникающем на фоне воспаления и другими подтипами колоректального рака, которые развиваются без каких-либо признаков явного воспалительного процесса. немаловажное влияние на развитие спорадического колоректального рака и колит- ассоциированного рака оказывает кишечная микробиота. Злокачественные опухоли толстой кишки, вне зависимости от формы колоректального рака, имеют повышенную экспрессию провоспалительных цитокинов. При колоректальном раке роль туморинфильтри-рующих иммуноцитов и воспалительного микроокружения опухоли неоднозначна, с одной стороны, они осуществляют противоопухолевую иммунную защиту, с другой, проонкогеннную функцию. В перспективе, противовоспалительные биопрепараты смогут снизить риск развития колоректального рака.

https://doi.org/10.37469/0507-3758-2018-64-1-34-40
PDF

Библиографические ссылки

Atreya I., Neurath M.F. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies//Expert Rev. Anticancer Ther. -2008. -Vol. 8. -P. 561-572.

Babyatsky M., Lin J., Yio X. et al. Trefoil factor-3 expression in human colon cancer liver metastasis//Clin. Exp. Metastasis. -2009. -Vol. 26. -P 143-151.

Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease//Cancer Cell. -2005. -Vol. 7. -P. 211-217.

Becker C., Fantini M.C., Schramm C. et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 transsignaling//Immunity. -2004. -Vol. 21. -P. 491-501.

Bettelli E., Carrier Y., Gao W. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells//Nature. -2006. -Vol. 441. -P 235-238.

Bierie B., Moses H.L. Transforming growth factor beta (TGF-beta) and inflammation in cancer//Cytokine Growth Factor Rev. -2010. -Vol. 21. -P 49-59.

Bollrath J., Phesse T.J., von Burstin V.A. et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cellcyclecellcycle progression during colitis-associated tumorigenesis//Cancer Cell. -2009. -Vol. 15. -P. 91-102.

Bonecchi R., Galliera E., Borroni E.M. et al. Chemokines and chemokine receptors: an overview//Front Biosci. -2009. -Vol. 14. -P. 540-551.

Coussens L.M., Werb Z. Inflammation and cancer//Nature. -2002. -Vol. 420. -P. 860-867.

Dann S.M., Spehlmann M.E., Hammond D.C. et al. IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens//J. Immunol. -2008. -Vol. 180. -P 6816-6826.

DeNardo D.G., Barreto J.B., Andreu P. et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages//Cancer Cell. -2009. -Vol. 16. -P. 91-102.

Deschoolmeester V., Baay M., Van Marck E. et al. Vermorken Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients//BMC Immunol. -2010. -Vol. 11. -P. 19. - DOI: 10.1186/1471-2172-11-19

Dominitzki S., Fantini M.C., Neufert C. et al. Cutting edge: transsignaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4-CD25 T cells//J. Immunol. -2007. -Vol. 179. -P. 2041-2045.

Ellmerich S., Djouder N., Scholler M., Klein J.P Production of Cytokines by monocytes, epithelial and endothelial cells activated by Streptococcus bovis//Cytokine. -2000. -Vol. 12. -P. 26-31.

Ellmerich S., Scholler M., Duranton B. et al. Promotion of intestinal Carcinogenesis by Streptococcus bovis//Carcinogenesis. -2000. -Vol. 21. -P 753-756.

Feagins L.A., Souza R.F., Spechler S.J. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer//Nat. Rev. Gastroenterol. Hepatol. -2009. -Vol.6. -P. 297-305.

Fenton J.I., Hursting S.D., Perkins S.N., Hord N.G. Interleukin-6 production induced by leptin treatment promotes cell proliferation in an Apc (Min) colon epithelial cell line//Carcinogenesis. -2006. -Vol. 27. -P 1507-1515.

Freitas M., Axelsson L.G., Cayuela C., Midtvedt T., Trugnan G. Microbial-host interactions specifically control the glycosylation pattern in intestinal mouse mucosa//Histochem Cell Biol. -2002. -Vol. 118. -P 149-161.

Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system//Nat. Rev. Immunol. -2009. -Vol. 9. -P 162-174.

Garrett W.S., Punit S., Gallini C.A. et al. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells//Cancer Cell. -2009. -Vol. 16. -P. 208-219.

Gratz I.K., Rosenblum M.D., Abbas A.K. The life of regulatory T cells//Ann N. Y Acad. Sci. -2013. -Vol. 1283. -P. 8-12.

Grivennikov S., Karin E., Terzic J. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitisassociated cancer//Cancer Cell. -2009. -Vol. 15. -P. 103-113.

Gueimonde M., Ouwehand A., Huhtinen H., Salminen E., Salminen S. Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease//World J. Gastroenterol. -2007. -Vol. 13. -P. 3985-3989.

Huycke M.M., Abrams V., Moore D.R. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA//Carcinogenesis. -2002. -Vol. 23. -P. 529-536.

Issa M., Vijayapal A., Graham M.B. et al. Impact of Clostridium difficile on inflammatory bowel disease//Clin. Gastroenterol. Hepatol. -2007. -Vol. 5. -P 345-351.

Ito H., Takazoe M., Fukuda Y. et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease//Gastroenterology. -2004. -Vol. 126. -P. 989-996; discussion 947.

Izcue A., Coombes J.L., Powrie F. Regulatory lymphocytes and intestinal inflammation//Annu. Rev. Immunol. -2009. -Vol. 27. -P. 313-338.

Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition//J. Clin. Invest. -2009. -Vol. 119. -P. 1420-1428.

Kim B.G., Li C., Qiao W. et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer//Nature. -2006. -Vol. 441. -P. 1015-1019.

Kitamura T., Biyajima K., Aoki M., Oshima M., Taketo M.M. Matrix metalloproteinase 7 is required for tumor formation, but dispensable for invasion and fibrosis in SMAD4-deficient intestinal adenocarcinomas//Lab Invest. -2009. -Vol. 89. -P. 98-105.

Kitamura T., Kometani K., Hashida H. et al. SMAD4-de-ficient intestinal tumors recruit CCR1-myeloid cells that promote invasion//Nat Genet. -2007. -Vol. 39. -P 467-475.

Klampfer L. The role of signal transducers and activators of transcription in colon cancer//Front Biosci. -2008. -Vol. 13. -P. 2888-2899.

Kollias G. Modeling the function of tumor necrosis factor in immune pathophysiology//Autoimmun Rev. -2004. -Vol. 3(Suppl 1). -P. S24-S25.

Kraus S., Arber N. Inflammation and colorectal cancer//Curr. Opin. Pharmacol. -2009. -Vol. 9. -P. 405-410.

Kruglov A.A., Kuchmiy A., Grivennikov S.I. et al. Physiological functions of tumor necrosis factor and the conиsequences of its pathologic overexpression or blockade: mouse models//Cytokine Growth Factor Rev. -2008. -Vol. 19. -P. 231-244.

Laghi L., Bianchi P., Miranda E. et al. CD3-cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study//Lancet Oncol. -2009. -Vol. 10. -P. 877-884.

Lakatos P.L., Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies//World J. Gastroenterol. -2008. -Vol. 14. -P. 3937-3947.

Lee H., Herrmann A., Deng J.H. et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors//Cancer Cell. -2009. -Vol. 15. -P. 283-293.

Leppkes M., Becker C., Ivanov I.I. et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F//Gastroenterology. -2009. -Vol. 136. -P. 257-267.

Li B., Vincent A., Cates J. et al. Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site//Cancer Res. -2009. -Vol. 69. -P. 338-348.

Luo J.L., Tan W., Ricono J.M. et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin//Nature. -2007. -Vol. 446. -P. 690-694.

Maggio-Price L., Treuting P., Zeng W. et al. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice//Cancer Res. -2006. -Vol. 66. -P. 828-838.

Martin H.M., Campbell B.J., Hart C.A. et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer//Gastroenterology. -2004. -Vol. 127. -P. 80-93.

Nosho K., Baba Y., Tanaka N., Shima K. et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review//J. Pathol. -2010. -Vol. 222. -P. 350-366. - DOI: 10.1002/path.2774

Pagès F., Galon J., Dieu-Nosjean M.C. et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored//Oncogene. -2010. -Vol. 29. -P. 10931102. - DOI: 10.1038/onc.2009.416

Pickert G., Neufert C., Leppkes M. et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing//J. Exp. Med. -2009. -Vol. 206. -P. 1465-1472.

Pollard J.W. Tumor-educated macrophages promote tumor progression and metastasis//Nat. Rev. Cancer. -2004. -Vol. 4. -P. 71-78.

Popivanova B.K., Kitamura K., Wu Y et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis//J. Clin. Invest. -2008. -Vol. 118. -P. 560-570.

Rabizadeh S., Rhee K.J., Wu S. et al. Enterotoxigenic bacteroides fragilis: a potential instigator of colitis//Inflamm. Bowel. Dis. -2007. -Vol. 13. -P. 1475-1483.

Rowland I.R. The role of the gastrointestinal microbiota in colorectal cancer//Curr. Pharm Des. -2009. -Vol. 15. -P. 1524-1527.

Sakamoto K., Maeda S., Hikiba Y et al. Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth//Clin. Cancer Res. -2009. -Vol. 15. -P. 2248-2258.

Saleh M., Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer//Nat. Rev. Immunol. -2011. -Vol. 11. -P. 9-20. - DOI: 10.1038/nri2891

Scanlan P.D., Shanahan F., Clune Y et al. Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis//Environ Microbiol. -2008. -Vol. 10. -P. 789-798.

Suzuki A., Hanada T., Mitsuyama K. et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation//J. Exp. Med. -2001. -Vol. 193. -P. 471-481.

Tang Y., Katuri V., Srinivasan R. et al. Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis//Cancer Res. -2005. -Vol. 65. -P. 4228-4237.

Ueno K., Hazama S., Mitomori S. et al. Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells//Br. J. Cancer. -2009. -Vol. 101. -P. 1374-1381.

Uronis J.M., Muhlbauer M., Herfarth H.H. et al. Modulation of the intestinal microbiota alters colitisassociated colorectal cancer susceptibility//PLoS One. -2009. -Vol. 4. -P. e6026.

Vladimirova L.Y., Kit O.I., Nikipelova E.A. Resilts of monoclonal antibodies against EGFR-receptors application in patients with metastatic colorectal cancer//Journal of Clinical Oncology. -2013. -Vol. 31. -№15S. -С. 19047.

Waldner M.J., Neurath M.F. Cytokines in colitis associated cancer: potential drug targets?//Inflamm Allergy Drug Targets. -2008. -Vol. 7. -P. 187-194.

Wang S., Liu Z., Wang L., Zhang X. NF-kappaB signaling pathwaY., inflammation and colorectal cancer//Cell Mol. Immunol. -2009. -Vol. 6. -P. 327-234.

Weir T.L., Manter D.K., Sheflin A.M. et al. Stool micro-biome and metabolome differences between colorectal cancer patients and healthy adults//PLoS One. -2013. -Vol. 8. -P. e70803.

Wu N., Yang X., Zhang R. et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients//Microb. Ecol. -2013. -Vol. 66. -P. 462-470.

Wu S., Rhee K.J., Albesiano E. et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses//Nat. Med. -2009. -Vol. 15. -P. 1016-1022.

Wu Y., Zhou B.P. Inflammation: a driving force speeds cancer metastasis//Cell Cycle. -2009. -Vol. 8. -P. 3267-3273.

Wu Y., Deng J., Rychahou P.G., Qiu S., Evers B.M., Zhou B.P. Stabilization of snail by NF-kappaB is required for inflammationinduced cell migration and invasion//Cancer Cell. -2009. -Vol. 15. -P. 416-428.

Yang L., Moses H.L. Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer?//Cancer Res. -2008. -Vol. 68. -P. 91079111.

Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis//Dev. Cell. -2008. -Vol. 14. -P. 818-829.

Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment//Nat. Rev. Immunol. -2007. -Vol. 7. -P. 41-51.

Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3//Nat. Rev. Cancer. -2009. -Vol. 9. -P 798-809.

Лицензия Creative Commons

Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.